Adlai Nortye Ltd. (ANL )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ANL
- Company Adlai Nortye Ltd.
- Price $11.76
- Changes Percentage -17.33
- Change -2.465
- Day Low $11.49
- Day High $14.2
- Year High $17.25
- Year Low $0.88
- Market Cap $840,256,400
- Price Avg 50 EMA (D) $13.79
- Price Avg 200 EMA (D) $9.84
- Exchange NASDAQ
- Volume 144,252
- Average Volume 196,179
- Open $14.2
- Previous Close $14.22
- EPS -1.39
- PE -11.39
- Earnings Announcement 2027-03-03 12:00:00
- Shares Outstanding $53,080,000
Company brief: ADLAI NORTYE LTD. (ANL )
- Healthcare
- Biotechnology
- Mr. Yang Lu
- https://www.adlainortye.com
- KY
- N/A
- 01-03-2000
- US00704R1095
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.